OnBioVC NEWS:

- OnBioVC Announces Beta Launch of Service
- OnBioVC INDEX(TM) Updated thru JUN 2010
- OnBioVC 2Q10 Trend Analysis, now available
- OnBioVC 3Q10 Trend Analysis, coming soon

SEARCH THE OnBioVC DATABASE:

04

Mar

2010

Merus, B.V.: Series B $30.7M

Posted in I - Series B, Q - 1Q10, R - INTERNATIONAL, X - Antibody, X - Inflammation, X - Oncology

Merus (Netherlands) a preclinical-stage biopharmaceutical focused on antibody product candidates against targets in oncology, inflammation and infectious disease, closed a $30.7M Series B financing. Participants include Novartis Option Fund, Pfizer, Bay City Capital, Life Sciences Partners and Aglaia Biomedical Ventures.

Venture Capital Investors
5AM Ventures Advanced Technology Ventures Alta Partners ARCH Venture Partners Canaan Partners Care Capital Clarus Ventures Delphi Ventures De Novo Ventures Domain Associates Edmond de Rothschild Investment Partners Essex Woodlands Health Ventures Flagship Ventures Forward Ventures Foundation Medical Partners HBM Bioventures Healthcare Ventures Imperial Innovations Interwest Partners Kaiser Permanente Ventures Kleiner Perkins Life Sciences Partners Mohr Davidow Ventures Morgenthaler Ventures MPM Capital New Enterprise Associates New Leaf Venture Partners Novo Ventures Oxford Bioscience Partners Pappas Ventures Polaris Venture Partners Prospect Venture Partners Quaker BioVentures Sanderling Ventures SV Life Sciences Texas Emerging Technology Fund Third Rock Ventures Thomas McNerney Partners TPG Biotech TPG Growth TVM Capital U.S. Venture Partners Venrock Versant Ventures Wellcome Trust

OnBioVC Friends

IguanaBio
EyeOnFDA
Patent Baristas
Pharma's Cutting Edge
MedTechIQ
The Antibody Blog
BioJobBlog

OnBioVC Partners